On April 4, 2024, CRF signed a letter of support for Emixustat hydrochloride, a drug with potential for maintaining retinal health, to treat Stargart’s disease. Read the CRF Letter to Support Emixustat at PMDA here.
On April 4, 2024, CRF signed a letter of support for Emixustat hydrochloride, a drug with potential for maintaining retinal health, to treat Stargart’s disease. Read the CRF Letter to Support Emixustat at PMDA here.
Our website is open to all. Please click on the little blue man accessibility widget at the bottom left of the page if you’d like to customize our website for your needs.
